SCHEMBL5137540

SCHEMBL5137540

CCCCn1c(CN(CCc2ccc(OCC)c(OC)c2)Cc2ccc3c(c2)OCO3)cnc1-c1cccc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 13/20 0.53
HTR2B P41595 13/20 0.53
HTR2C P28335 12/20 0.53
TP53 P04637 4/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.45
ADRB1 P08588 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
DRD1 P21728 1/20 0.44
DRD4 P21917 1/20 0.44
SLC6A2 P23975 1/20 0.44
ADRA1D P25100 1/20 0.44
HTR1D P28221 1/20 0.44
SLC6A4 P31645 1/20 0.44
HTR7 P34969 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134864 0.96 HTR2A (0.57) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5135288 0.90 HTR2A (0.51) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5136312 0.89 HTR2A (0.44) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5136215 0.89 HTR2A (0.57) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5137390 0.86 C5AR1 (0.44) HTR2AHTR2BHTR2CTP53POLB
SCHEMBL4768999 0.86 C5AR1 (0.51) HTR2AHTR2BHTR2CSMN1; SMN2POLB
SCHEMBL5136966 0.86 HTR2A (0.43) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5136963 0.85 C5AR1 (0.47) HTR2AHTR2BHTR2CSMN1; SMN2POLB
SCHEMBL5136272 0.85 C5AR1 (0.43) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5136789 0.84 C5AR1 (0.42) HTR2AHTR2BHTR2CTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed